Analysts Set Expectations for Imunon Q1 Earnings

Imunon, Inc. (NASDAQ:IMNN) – Research analysts at Brookline Capital Management issued their Q1 2025 earnings estimates for Imunon in a research report issued to clients and investors on Thursday, November 7th. Brookline Capital Management analyst K. Dolliver anticipates that the company will post earnings of ($0.33) per share for the quarter. The consensus estimate for Imunon’s current full-year earnings is ($1.71) per share. Brookline Capital Management also issued estimates for Imunon’s Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.29) EPS and Q4 2025 earnings at ($0.30) EPS.

Imunon (NASDAQ:IMNN) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.04.

Several other research analysts have also recently commented on IMNN. EF Hutton Acquisition Co. I upgraded shares of Imunon to a “strong-buy” rating in a report on Monday, September 23rd. HC Wainwright lowered their price target on shares of Imunon from $14.00 to $12.00 and set a “buy” rating for the company in a report on Monday.

Imunon Stock Up 3.6 %

NASDAQ IMNN opened at $0.83 on Monday. Imunon has a 52 week low of $0.48 and a 52 week high of $3.65. The stock has a market capitalization of $49.77 million, a PE ratio of -0.44 and a beta of 2.14. The firm has a 50 day moving average of $1.01 and a two-hundred day moving average of $1.20.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.